argyrotsipi/train-dataset huggingface dataset:
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I should like my hon. Friend to write to me with the exact details of that case. The process for prescription by someone on the specialist register is well trodden; it is used for all sorts of unlicensed drugs, and it should be available. We are making a second opinion available to ensure that it can be brought to bear in cases such as these. I am interested in hearing about specific cases—this applies to everyone, not just to my hon. Friend—so that we can ensure that the appropriate clinical decisions can be made.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): If I may, Mr Speaker, I would like to add to my previous answer by congratulating my hon. Friend the Member for Watford, the former Business Minister, on all that he did to support business, enterprise and the case for capitalism while he was in his former job. I regret his departing from the Government, because he was a brilliant Minister. On the question ahead of me, so to speak, the Chair of the Select Committee, the hon. Member for Totnes (Dr Wollaston), is right to say that it is vital to bring forward these clinical trials, and that the pharmaceutical companies that provide the oils have not pushed forward the trials in the way that would normally happen. We have therefore stepped in to try to make them happen, but we do need the calls to be answered.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I am sure that the BPNA will have heard that testimony from the right hon. Gentleman. Of course, the BPNA is independent of Government, and we have to follow the clinical judgments made by the relevant organisations, whether a royal college or, as in this case, an association. What I have done is ensure that a second opinion is available, because the BPNA guidance is merely guidance; it is not absolute. A clinician on the specialist register can make a decision according to what they think is best for the patient in front of them.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I entirely understand the hon. Gentleman’s point, and I feel the same way as he does about the urgency of these cases. The need to get a second opinion can be actioned immediately, and it will be, because the crucial point is that unlicensed medicines cannot be prescribed without a clinician. There are just over 95,000 clinicians on the specialist register, and any of those who have expertise in this area can, if their clinical judgment allows, make these prescriptions. That can happen right now.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Timothy Paul Loughton (Conservative, Centre-right): I was very supportive of the case of Alfie Dingley and the change in the law. The Secretary of State is absolutely right that this must be based on clinical decisions. However, given that there are several hundred children suffering from severe intractable epilepsy, is not the problem that the guidance from NHS medical bodies is just too stringent? Is it true that only two NHS prescriptions have actually been issued to date? Given that Teagan Appleby has had at least a dozen prescribed drugs—I will not list them, to avoid stressing Hansard—as well as a nerve stimulator, what would be the downside of allowing her access to medical cannabis now?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): My hon. Friend makes a good point. More than 80 prescriptions have been made, but that is for both THC and CBD. Of course, THC brings risks—the active elements within cannabis do bring risks. There are also benefits, as I have seen very clearly. It must be for a clinician to decide the balance of those risks. I have enormous sympathy for the families, having heard their personal testimony about the massive benefits for their children, who sometimes, as my right hon. Friend the Member for Hemel Hempstead (Sir Mike Penning) said, have 300 seizures a day. Having seen that and looked them in the eye, I understand the benefits. However, it has to be a clinician who makes that judgment. I am not medically qualified and cannot overrule a clinician, but there are clinicians available who can provide a second opinion, and that is what I can ensure.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): The evidence of clinical trials from elsewhere can and should be used. All international clinical evidence should be brought to bear on such decisions and has been in the case of CBD. As for how quickly things will happen, the answer is, as the hon. Lady would imagine, as soon as possible.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Michael Louis David Fabricant (Conservative, Centre-right): The SNP spokesman was spot on. This is about not just drugs such as ketamine and diazepam, but beta blockers, which can also be extremely dangerous in the wrong hands. Will my right hon. Friend speak to the Home Secretary and say, "Look. This is a medical treatment. It shouldn’t be a controlled drug as such"? This treatment should not be stopped at our borders, particularly when it appears that not enough people are prepared to prescribe it.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I spoke to the Home Secretary this morning about the issue, and we proposed to see it as a health matter, not a borders matter. The Border Force officers were merely following the rules, and the question is about whether the drug is licensed. If it is not licensed, but it is controlled, the question is about whether it has clinical sign-off. The truth is that the compound does have negative effects, so it must be a controlled drug. I do not support the legalisation of all cannabis. Unless one supports the legalisation of cannabis in all cases, it has to be a controlled drug, which leads us to where we are. We must get the evidence of the medical and clinical benefits that the families have emphatically explained, and I want to see this situation dealt with properly.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): We have ensured that all the patients who received access to medicinal cannabis on an exceptional basis before the law changed on 1 November can continue to access it. If that is not the case in any instance, I want to know about that so that we can fix it. Alfie Dingley would be eligible for these drugs if a clinician were prepared to sign off the benefits for Alfie, and such decisions must be led by clinicians. I am doing everything I can to get the evidence and second opinions in place and to ensure that the process works as well as possible. That is what I can do. What I cannot do—it would be unreasonable for any Health Secretary to do so—is overrule clinical decision making in individual cases. That would be wrong, and I do not think that any Member of this House would propose that I should do it.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Christopher Heaton-Harris (Conservative, Centre-right): A number of us have been written to by constituents about such cases, and I have corresponded with the Secretary of State about Julie and Stuart Young, the parents of Lloyd, for example. Clinical trials have been mentioned across the House, but a piece of legislation is already in place. The Access to Medical Treatments (Innovation) Act 2016, which was sponsored by me in the Commons and by Lord Saatchi in the other place, seems ideally suited to help us through this sticky situation.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): Yes, we are looking carefully at how we can use that legislation as effectively as possible. Understanding the medical consequences of any use of a drug is incredibly helpful evidence for where it should be prescribed further, and that is the thrust of the 2016 Act.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): The BPNA is going to have to answer for itself about the way in which its representatives conducted themselves in front of the Select Committee. It is independent. Understandably, in medicine the bodies that make clinical guidance do not direct the answer for that clinical guidance to the Secretary of State. I understand the hon. Lady’s strength of feeling and that of others. I also understand the strength of feeling of the parents. I understand what a desperate situation they are in, and I am trying to make sure that it can be resolved and that they can get the drugs. I make one point to the hon. Lady: the very exercise of a clinical trial requires us to get the drugs to some children. I very much hope, therefore, that the start of a clinical trial can help to get the drugs to the people who need them. We do not have to wait for the results.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Victoria Grace Ford (Conservative, Centre-right): Although medicinal cannabis can have great benefits for some epileptic children, we should not forget the devastating impact that cannabis can have and its long-term impact on psychosis and schizophrenia. [Interruption.] I speak from personal experience of living with an affected family member. It is right that this is dealt with on a case-by-case basis. How soon will updated training be available for our health professionals?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): The updated training will be available imminently. There are risks as well as upsides, and it is absolutely right that it is clinicians who make the judgment in respect of every decision and based on the individual patient. That, I am afraid, is the way in which medicine always has been—and, I imagine, always will be—practised in this country.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Brett Charles Anthony Elphicke (Conservative, Centre-right): My constituent Teagan Appleby suffers horrendously with one of the worst cases of child epilepsy in the United Kingdom. It has been heartrending to go round to her house to see her suffering. To see how her mother, Emma, copes with the challenge is inspiring Legal heroin, morphine, has been prescribed in this country for many decades. Why can we not have legal cannabis, too? Is it not high time that the NHS got on with changing the guidelines to make sure that medicinal cannabis is available, rather than wasting time arresting Emma at Southend airport, which is quite the wrong thing to see?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Simon Richard Clarke (Conservative, Centre-right): I commend the Secretary of State for his statement. I, like many others in this House, have had constituents visit me to make powerful, personal cases on the impact they think cannabis oil could have for their children. Will he join me in praising the work of the campaign group End Our Pain, which has done such a good job of highlighting this issue and making sure that we in this House are aware of the situation and of the benefits it can bring?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): One of the great frustrations for me, for the Home Secretary and, of course, for the families is that, before the law was changed on 1 November, that course of action was open. For a few dozen cases, the Home Secretary made those special licences to allow for the use of medicinal cannabis. He and I changed the law together to try to make sure that medicinal cannabis is available on a mainstream basis. Now it is available on a mainstream basis, as a normal drug, it therefore needs clinical sign-off. The problem is there are so many cases where that clinical sign-off has not been forthcoming. That is a source of immense frustration to me, as I hope the hon. Lady can imagine, and it is what we are trying to resolve.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Luke Patrick Graham (Conservative, Centre-right): Does my right hon. Friend agree that we should be led by evidence? As our scientific knowledge continues to progress, so should the views and the laws made in this House. Will he provide more clarity, not just in this instance but as new and more radical drugs become available in the near future, on how our constituents and this House could benefit and push through laws more quickly?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): My hon. Friend makes a very important point. To ensure that the use of medical cannabis becomes mainstream, we need to ensure that the evidence base is there. Essentially, doctors think there is a much deeper evidence base for CBD than for THC. There is a broader point, which is that the medical profession and this House need to keep up to speed with the evidence as it is developed. In this case, that means going out of our way to develop the evidence and to have clinical trials in which some of the patients who want the drug can participate. That will provide the evidence base that allows the vast array of specialists to prescribe it.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I will look at that idea and discuss it with the NHS. The training programme that we are putting in place is intended to raise awareness of the evidence and the change in rules among the profession—among doctors and the specialist prescribing doctors on the register. Ultimately, it is only with clinical sign-off that we allow any drug to be prescribed. That is where the training needs to be in the first instance, but I will look at the hon. Lady’s suggestion of doing it more broadly.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Rebecca Faye Clark (Pow) (Conservative, Centre-right): Anyone who goes through the heart-rending experience of seeing a very sick family member suffer will know that they would do anything to help that person, often reaching the point of desperation. People need to be confident that they can get hold of cannabis-based medicines if it is appropriate and that those medicines are safe. In this instance, there is a lot riding on the shoulders of our doctors. Will my right hon. Friend assure us that doctors are being given the right guidance to do what is right for patients, but also that they will not be blamed if something goes wrong?
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): Yes, of course; I am very happy to do that. Perhaps I should take this opportunity to welcome the new public health Minister, the Under-Secretary of State for Health and Social Care, my hon. Friend the Member for South Ribble (Seema Kennedy) to her post. She will, no doubt, have listened to all the questions today. She and I will be working on making this happen I would add to the hon. Lady’s list, because this is not just about the Home Office and the Department of Health and Social Care; it is about making sure that the independent medical establishment has confidence in the evidence that is presented. It is not enough for her and I to have confidence as lay politicians; it is important that the professionals who put their signature on the line have confidence in the evidence as well.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): My hon. Friend makes an important point. The Border Force should not be criticised in this case, because it was following the rules: if a clinician has not signed something off it cannot come in. It is incumbent on us on the health side to sort out this problem. He makes a broader point, however, that this is a completely separate issue to the recreational use of cannabis. I do not support a change in the rules on the recreational use of cannabis; this is about the specialist provision of drugs to some children who are the most vulnerable people in society, and the need to ensure that the medical benefits of such drugs can be brought to bear on people who really need them.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): I am saying that if a patient needs medicinal cannabis, and if a clinician will sign off on that need, the prescription can happen. The guidance from the association does not override the individual judgment of that clinician. That can happen but, because it has not been happening in many cases that have been brought to light, some privately and some very publically, I am putting in place a system of second opinions to ensure that we can get that clinical decision right, at the same time as developing a stronger evidence base for the future.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): Those guidelines are not a matter for the Home Secretary; they are guidelines in the health space, although the association that writes them does not report directly to me but is independent. Those guidelines do not prevent a physician who is on the specialist register of the General Medical Council from prescribing. If anybody has been told that they do, they do not; it is up to the individual professional judgment of a specialist clinician on the register to prescribe or not.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): Yes. My heart goes out to the hon. Lady’s constituent and her family. One of the purposes of the evidence gathering that we are doing, and of the calls of the national institute for trials, is to provide the evidence on which the NHS could routinely provide those medicines. At the moment, we have the ability for specialists to prescribe in the interim, but I want to get the evidence base in place for the longer term.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): We looked at observational trials, but the problem is that they do not build the evidence base that a full RCT does. A full RCT also allows some patients to get access while the trial is ongoing, so it is in fact a better proposal. It means that some patients can get the treatment now for the purposes of the trial, and then we can get a full evidence base for the long term, as was mentioned previously.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): It is a source of deep frustration to me that the change in the law to normalise the use of medicinal cannabis has, exactly as the hon. Gentleman says, meant that, because a clinical decision is needed for a prescription, and because in many cases clinical decisions are not forthcoming, many parents who entirely understandably think that their child would benefit from medicinal cannabis now find that they cannot get a clinician to sign it off. That is at the root of the problems that we are trying to tackle today.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): He will be able to get it now if a clinician is prepared to sign off on it being the right thing for him. If that is not forthcoming now, I have announced today a system of second opinions to allow people to get the clinical sign-off that they need.
Access to Medical Cannabis — House of Commons, 2019-04-08
Topic: Health
Matthew John David Hancock (Conservative, Centre-right): They must be taken into account. It comes down to the question of the complexity of cannabis and the many dozens of active agents in it; CBD and THC, which we have mostly been discussing today, are the main ones. Many drugs have similarly complex interactions. Modern science and medicine are capable, in a controlled environment, of getting to the bottom of which ones have the effect. That is why it is better to do a full RCT with the full scientific structure around it, rather than an observational trial. That will get the drugs to the people who need them quickly, and will provide the evidence base. I hope that that satisfies the hon. Gentleman that, in that space, we are doing as much as we can. On the timing, I want it to happen as quickly as possible.
Online Harms White Paper — House of Commons, 2019-04-08
Topic: Health
Jeremy Paul Wright (Conservative, Centre-right): The right hon. Gentleman makes a good point. As he will recognise, the White Paper deals with some of the harms that he mentions—serious violence and self-harm, in particular. It is right that all of government is behind the strategy. It is important that we ensure that the links between what this regulator does, what the health service does and what many other bodies within and outside Government do are sustained On social media, we all recognise that we cannot put the genie back in the bottle. Social media will continue to be a significant element in the lives of young people, in particular, with all the challenges to their mental health that we know it brings. Those who promote platforms for the kind of user-generated interaction that we are concerned with in this White Paper must accept that they can do something about some of the harmful material on those platforms. If they choose to do so, they will have nothing to fear from our proposals; if they choose not to, they will find that consequences follow.
Online Harms White Paper — House of Commons, 2019-04-08
Topic: Health
Jeremy Paul Wright (Conservative, Centre-right): The hon. Lady makes a very important point. She will see in the White Paper that we think the prohibition of material that promotes suicide is exactly something that the online platforms should concern themselves with. They need to think why it is that in some cases when people enter certain search terms what comes up is material promoting suicide, rather than advice and guidance on what could be done to help. That is exactly the kind of action we will expect online companies to take. If they do not, it will be hard for them to persuade the regulator that they are doing all they reasonably can to keep their users safe.
Points of Order — House of Commons, 2019-04-08
Topic: Culture
John Simon Bercow (Conservative, Centre-right): What I would say to the hon. Gentleman, to whom I am grateful for his point of order, is that I have been somewhat blindsided on the matter, in that I was not aware of his intention to raise it, about which I make no complaint—it is obviously a matter of earnest preoccupation to him. However, what I mean is that I have not had the chance to take advice, and I am not sure what the appropriate response would be What I would say off the top of my head is that, in light of the very genuine concern the hon. Gentleman has expressed, I should have thought that it would be fitting and potentially helpful if the Secretary of State for Digital, Culture, Media and Sport were to speak to the hon. Gentleman about this matter and, dare I say, perhaps also to consult the right hon. Member for Belfast North (Nigel Dodds), who leads his party in this place, in the hope of brokering a solution, which will bring a smile to the face of the hon. Gentleman.